The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
**Background:** Persistence and adherence to disease-modifying therapies (DMTs) affects treatment efficacy and economic outcomes, both of which contribute to overall patient disease burden. Current literature suggests that patients with multiple sclerosis (MS) who adhere to DMT for 12 months have fe...
Main Authors: | Gabriel Pardo, Elmor D. Pineda, Carmen D. Ng, Daniel Sheinson, Nicole G. Bonine |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2022-04-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/jheor.2022.33288 |
Similar Items
-
The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
by: Gabriel Pardo, et al.
Published: (2022-04-01) -
Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis
by: Caroline Kelley Geiger, et al.
Published: (2023-09-01) -
Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab
by: Caroline K. Geiger, et al.
Published: (2023-07-01) -
Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
by: Gisela Zanga, et al.
Published: (2021-10-01) -
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis
by: Burks J, et al.
Published: (2017-04-01)